Targeting mutations in cancer-related enzymes to improve treatment outcomes
Official title: Targeting isocitrate dehydrogenase mutations by enzyme hyperactivation
Funded at Sloan-Kettering Inst Can Research · NIH-11021054 · Data updated 2026-11-12
This study is looking at how changes in certain enzymes can make aggressive cancers like acute myeloid leukemia harder to treat, and it's working on finding new ways to help patients who don't respond to current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $474,760 |
| NIH project number | 5R01CA290231-02 |
| Project ID | NIH-11021054 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients diagnosed with acute myeloid leukemia or other cancers associated with IDH mutations.
✕Less likely to help
Patients without IDH mutations or those with cancers not related to isocitrate dehydrogenase may not benefit from this research.
What this research studies
This research focuses on understanding how mutations in isocitrate dehydrogenase (IDH) enzymes contribute to various aggressive cancers, particularly acute myeloid leukemia (AML). The study aims to develop new treatment strategies that go beyond simply inhibiting these enzymes, as many patients do not respond to current IDH inhibitors. By investigating the mechanisms of resistance and identifying specific mutations that affect treatment efficacy, the research seeks to enhance patient outcomes through innovative therapeutic approaches.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with IDH-mutant cancers, improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results with IDH inhibitors, but this approach aims to explore novel strategies to overcome resistance, making it a potentially groundbreaking area of investigation.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Intlekofer, Andrew Michael — Sloan-Kettering Inst Can Research
- Study coordinator: Intlekofer, Andrew Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.